Review: smooth muscle relaxants improve symptoms and reduce pain in irritable bowel syndrome

William D Chey

_Evid. Based Med._ 2001;6;153-
doi:10.1136/ebm.6.5.153

Updated information and services can be found at:
http://ebm.bmjjournals.com/cgi/content/full/6/5/153

These include:

**Rapid responses**
You can respond to this article at:
http://ebm.bmjjournals.com/cgi/eletter-submit/6/5/153

**Email alerting service**
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

**Topic collections**
Articles on similar topics can be found in the following collections
- Irritable bowel syndrome (132 articles)
- Drugs: gastrointestinal system (378 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to _Evidence-Based Medicine_ go to:
http://www.bmjjournals.com/subscriptions/
Review: smooth muscle relaxants improve symptoms and reduce pain in irritable bowel syndrome


QUESTION: In patients with the irritable bowel syndrome (IBS), are smooth muscle relaxants safe and efficacious for global improvement of symptoms?

Data sources
Randomised controlled trials were identified by searching Medline with the terms colonic disease, functional, irritable bowel syndrome, and randomized trial; Current Contents; and bibliographies of relevant trials, meta-analyses, and reviews. Drug companies were also contacted.

Study selection
Trials were selected if they were double blind studies that compared muscle relaxants with placebo, ≥51% of patients had IBS, the drugs studied had myorelaxant properties, and ≥1 end point of global assessment of symptoms, abdominal pain, constipation, or abdominal distension was included.

Data extraction
Data were extracted on study quality, patient characteristics and numbers, drug and dosage, treatment duration, and outcomes.

Main results
23 trials (1888 patients) met the inclusion criteria. 6 drugs were studied: cimetropium bromide (5 trials), hyoscine butyl bromide (3 trials), mebeverine (5 trials), otilium bromide (4 trials), pinaverium bromide (2 trials), and trimebutine (4 trials). All drugs analysed together and each drug analysed separately, except pinaverium alone, showed improvement in global symptom ratings (table). All drugs combined (and otilium and cimetropium alone) reduced pain (table). Abdominal distension was improved with all drugs (table), but constipation or transit was not. The percentage of patients with adverse effects did not differ for all drugs compared with placebo or for individual drugs.

Conclusion
Smooth muscle relaxants improve the global rating of symptoms and reduce pain in patients with irritable bowel syndrome.

Smooth muscle relaxants v placebo for irritable bowel syndrome (trial duration 3 d to 24 wks)*

<table>
<thead>
<tr>
<th>Improvements</th>
<th>Drug</th>
<th>Number of studies</th>
<th>Drug</th>
<th>Placebo</th>
<th>RBI (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global</td>
<td>All</td>
<td>22</td>
<td>56%</td>
<td>38%</td>
<td>49% (37 to 61)</td>
<td>6 (5 to 8)</td>
</tr>
<tr>
<td></td>
<td>Mebeverine</td>
<td>4</td>
<td>52%</td>
<td>37%</td>
<td>47% (9 to 84)</td>
<td>4 (6 to 31)</td>
</tr>
<tr>
<td></td>
<td>Cimetropium</td>
<td>5</td>
<td>60%</td>
<td>40%</td>
<td>63% (29 to 92)</td>
<td>4 (3 to 9)</td>
</tr>
<tr>
<td></td>
<td>Trimebutine</td>
<td>4</td>
<td>53%</td>
<td>24%</td>
<td>98% (63 to 117)</td>
<td>5 (4 to 7)</td>
</tr>
<tr>
<td></td>
<td>Otilium</td>
<td>3</td>
<td>97%</td>
<td>34%</td>
<td>60% (33 to 87)</td>
<td>5 (4 to 9)</td>
</tr>
<tr>
<td></td>
<td>Hyoscine</td>
<td>3</td>
<td>53%</td>
<td>42%</td>
<td>26% (7 to 124)</td>
<td>10 (2 to 32)</td>
</tr>
<tr>
<td>Pain</td>
<td>All</td>
<td>11</td>
<td>53%</td>
<td>41%</td>
<td>30% (16 to 45)</td>
<td>9 (6 to 16)</td>
</tr>
<tr>
<td></td>
<td>Otilium</td>
<td>3</td>
<td>47%</td>
<td>29%</td>
<td>62% (30 to 96)</td>
<td>7 (4 to 12)</td>
</tr>
<tr>
<td></td>
<td>Cimetropium</td>
<td>1</td>
<td>87%</td>
<td>27%</td>
<td>198% (81 to 253)</td>
<td>2 (2 to 5)</td>
</tr>
<tr>
<td>Distention</td>
<td>All</td>
<td>6</td>
<td>44%</td>
<td>35%</td>
<td>26% (6 to 46)</td>
<td>12 (7 to 46)</td>
</tr>
</tbody>
</table>

*Abbreviations defined in glossary; RBI, NNT, and CI calculated from data in article.

COMMENTARY
IBS represents a heterogeneous group of disorders presenting with similar clinical symptoms. Altered motility is thought to be important in a subset of patients with IBS, and this concept forms the foundation for the use of smooth muscle relaxants.

3 recent meta-analyses, including the review by Poynard et al, have evaluated smooth muscle relaxants for IBS. Each found such agents better than placebo for global improvement and abdominal pain. The latest, the review by Poynard et al, differs from its predecessors by excluding peppermint oil and dicyclomide bromide and including 6 additional randomised, non-English language trials. Although smooth muscle relaxants appear superior to placebo, Poynard et al suggest that only approximately 50% of treated patients will experience global improvement and only 40% will have an improvement in abdominal pain. In addition, the results do not indicate which individuals are most likely to improve with these agents. Perhaps most important, only 1 of the drugs included in this meta-analysis, hyoscine, is available in the US, and it showed the least benefit for global improvement or abdominal pain over placebo.

If one accepts the issues noted above, it seems reasonable to conclude that as a class, smooth muscle relaxants can benefit a subset of patients with IBS. Unfortunately, whether the results are generalisable to agents available to physicians in the US remains an open question.

William D Chey, MD
University of Michigan Health Systems
Ann Arbor, Michigan, USA